Nonalcoholic fatty liver disease (NAFLD) or fatty liver is the most common cause for chronic liver disease in the US and is a significant public health concern. It is estimated that 1 in 3 American adults have fatty liver. Among people with fatty liver, 20-30% progress to metabolic dysfunction-associated steatotic liver disease (MASLD), a condition characterized by injury and inflammation in liver cells, which can eventually lead to advanced fibrosis, cirrhosis, and liver cancer. It is estimated that 5% of the US population has MASLD. In the US, rates of NAFLD are projected to increase from 83.1 and 16.52 million (2015) to 100.9 million and 27 million by 2030, respectively. It is therefore crucial to increase awareness about fatty liver and re-enforce patient care pathways to combat the growing burden of this condition, particularly for vulnerable populations and those at higher risk. The overall goal of this 60-minute presentation is to address these gaps to improve how MASLD is currently screened, diagnosed, and managed. Specifically, we will focus on how primary care professionals (PCPs) can collaborate with other specialist clinicians to better identify patients at risk of developing MASLD and optimize care.
- Provider:Boston University Chobanian & Avedisian School of Medicine
- Activity Link: https://cme.bu.edu/node/25694
- Start Date: 2024-07-31 05:00:00
- End Date: 2024-07-31 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all